Encouragingly, preclinical assessment of the third-generation epigenetic modifying drugs ivosidenib (an isocitrate dehydrogenase 1 inhibitor) and tazemetostat (an EZH2 inhibitor) show enhanced potency and broader spectrum of cytotoxicity for hematological malignancies and solid cancers (Italiano et al., 2018). The gene discussed is EZH2; the disease is hematologic disorder.